$SRXH

SRX Global (SRXH) will acquire CERo Therapeutics, a cellular immunotherapy company, to accelerate development of CER-1236 for blood cancers. The deal combines SRX's public infrastructure with CERo's oncology platform, aiming to enhance capital access and operational resources. CER-1236 is in Phase 1 trials, with preliminary data showing no dose-limiting toxicities in recent cohorts. The transaction is subject to closing conditions and regulatory approvals.

SRX Global agreed to acquire CERo Therapeutics from CERo Therapeutics Holdings. The deal includes $1M in stock, $8.25M in debt forgiveness, and assuming $1.56M in liabilities. The companies also extended a note's maturity to align with the transaction timeline.

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Stock Purchase Agreement On October 6, 2026, SRX Global Inc., a Delaware corporation formerly known as SRx Health Solutions, Inc. (the “Company” or “SRX”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) wi

SRX Global allocated $1.5M to debut AI-driven ETFs on EMJX, with the first offering a digital asset hedging strategy. Eric Jackson will manage the ETFs, and Kupa AI will handle launch logistics. The ETFs are expected to launch in Q1 2027, with SRX planning to distribute holdings to shareholders. According to an SEC filing.

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered b

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (“Buye

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accre

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.